Nucleophosmin delocalization in thyroid tumour cells.
Nucleophosmin (NPM) is a multifunctional nucleolar protein that, depending on the context, can act as oncogene or tumour suppressor. Mutations of the NPM1 gene induce delocalization of NPM in acute myeloid leukaemia. Differently, in solid tumours, only NPM overexpression, but not delocalization, has been so far reported. Here, NPM localization in thyroid tumours was investigated. By using immunohistochemistry, we show increase of NPM cytoplasmic localization in follicular adenomas and papillary carcinomas compared to normal thyroid tissue (p = 0.0125 and <0.0001, respectively). NPM1 mutations commonly found in human leukaemia are not present in thyroid tumours. Immunofluorescence in cultured cell lines was utilized to discriminate between nucleolar and nuclear localization. We show that in thyroid cancer cell lines NPM localizes both in the nucleolus and in nucleus, while in non-tumorigenic thyroid cell lines localizes only in nucleolus. Either presence of the histone deacetylase inhibitor trichostatin A or absence of thyroid-stimulating hormone induces NPM nuclear localization in non-tumorigenic thyroid cell lines.
Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Piazzale Kolbe 1, 33100 Udine, Italy.
Annalisa
A
Pianta
Cinzia
C
Puppin
Nadia
N
Passon
Alessandra
A
Franzoni
Milena
M
Romanello
Gianluca
G
Tell
Carla
C
Di Loreto
Stefania
S
Bulotta
Diego
D
Russo
Giuseppe
G
Damante
D018263:Adenocarcinoma, Follicular / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002466:Cell Nucleolus / Q000378:metabolism / Q000473:pathology; D002467:Cell Nucleus / Q000378:metabolism / Q000473:pathology; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D009687:Nuclear Proteins / Q000378:metabolism*; D000090243:Nucleophosmin; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D013972:Thyrotropin / Q000172:deficiency / Q000494:pharmacology
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D006877:Hydroxamic Acids; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; C012589:trichostatin A; D013972:Thyrotropin
Blood. 2007 Feb 1;109(3):874-85
17008539
Eur J Endocrinol. 1999 May;140(5):447-51
10229912
Endocrinology. 1997 Jun;138(6):2227-32
9165005
Nat Rev Cancer. 2006 Jul;6(7):493-505
16794633
Cancer Res. 1992 Jun 15;52(12):3372-7
1596895
Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):260-9
17315034
Trends Endocrinol Metab. 2008 May-Jun;19(4):138-45
18337114
J Biol Chem. 1987 Mar 25;262(9):4048-52
3549723
J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):391-402
10030688
J Pathol. 1996 Jan;178(1):48-52
8778315
Endocr Relat Cancer. 2009 Sep;16(3):715-31
19218279
Urology. 2004 Oct;64(4):839-44
15491744
Cancer Res. 2003 Oct 15;63(20):6716-25
14583466
Haematologica. 2007 Apr;92(4):519-32
17488663
Endocr Relat Cancer. 2007 Dec;14(4):957-77
18045949
Biochem Biophys Res Commun. 2010 Jul 2;397(3):499-504
20515654
Mol Cell Biol. 2009 Sep;29(18):5115-27
19581289
J Endocrinol Invest. 2001 Mar;24(3):RC10-2
11314755
Bioessays. 1998 Aug;20(8):615-26
9780836
Blood. 2010 Apr 22;115(16):3341-5
19666870
Proc Natl Acad Sci U S A. 1980 Jun;77(6):3455-9
6106191
Prostate. 1999 Jun 1;39(4):298-304
10344220
Endocrinol Metab Clin North Am. 2008 Jun;37(2):389-400, ix
18502333
N Engl J Med. 2005 Jan 20;352(3):254-66
15659725
Exp Cell Res. 1992 Nov;203(1):174-81
1426041
J Soc Gynecol Investig. 1997 Nov-Dec;4(6):298-304
9408885
Endocrinology. 1989 Jun;124(6):2889-94
2542003
J Clin Endocrinol Metab. 2005 Oct;90(10):5692-7
16076943
Cell. 1989 Feb 10;56(3):379-90
2914325